CVSIOTCPharmaceutical PreparationsFiscal year ends December 31
CV Sciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.01−0.00 (-21.13%)
Close on Oct 19, 2026
- Market cap
- $2.30M
- P/E (TTM)
- –
- Dividend yield
- –
CV Sciences, Inc. revenue by segment
By business segment
| Revenue | Q3 22 | Q2 22 | Q1 22 | Q4 21 | Q3 21 | Q2 21 | Q1 21 | Q4 20 | Q3 20 | Q2 20 | Q1 20 | Q4 19 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Consumer Products Segment | $3.75M | $4.14M | $4.45M | $4.97M | $5.11M | $5.13M | $4.84M | $5.20M | $5.56M | $5.40M | $8.27M | $9.33M | 100.0% | -26.6% |
| Specialty Pharmaceutical Segment | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | 0.0% | – |
| Operating income | Q3 22 | Q2 22 | Q1 22 | Q4 21 | Q3 21 | Q2 21 | Q1 21 | Q4 20 | Q3 20 | Q2 20 | Q1 20 | Q4 19 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Specialty Pharmaceutical Segment | -$1.00K | -$27.00K | -$35.00K | -$5.29M | -$294.00K | -$109.00K | -$73.00K | -$213.00K | -$302.00K | -$647.00K | -$1.21M | -$1.03M | -99.7% |
| Consumer Products Segment | -$891.00K | -$2.29M | -$1.48M | -$3.55M | -$2.69M | -$3.40M | -$3.04M | -$9.25M | -$2.85M | -$4.01M | -$4.11M | -$6.32M | -66.8% |
By product or service
By region
From the segment and revenue-disaggregation notes of CV Sciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.